Depressive symptoms and risk of functional decline and death in patients with heart failure  by Vaccarino, Viola et al.
Depressive Symptoms and Risk of Functional
Decline and Death in Patients With Heart Failure
Viola Vaccarino, MD, PHD,* Stanislav V. Kasl, PHD,† Jerome Abramson, PHD,*
Harlan M. Krumholz, MD, FACC†‡§
Atlanta, Georgia, and New Haven, Connecticut
OBJECTIVES We sought to examine whether depressive symptoms are associated with poorer prognosis in
patients with heart failure.
BACKGROUND Depression is an established risk factor for poor outcome in patients with coronary heart
disease (CHD). Little is known of its role in patients with heart failure.
METHODS We prospectively followed 391 patients $50 years of age who met criteria for decompensated
heart failure on hospital admission. The outcome of the study was death or decline in
activities of daily living (ADL) at six months, relative to baseline. Depressive symptoms were
measured at baseline by means of the Geriatric Depression Scale, Short-Form, with 6 to 7
symptoms, 8 to 10 symptoms and $11 symptoms indicating mild, moderate and severe levels
of depressive symptoms, respectively.
RESULTS There was a strong and graded association between the severity of depressive symptoms at
baseline and the rate of the combined end point of either functional decline or death at six
months. After adjustment for demographic factors, medical history, baseline functional status
and clinical severity, patients with $11 depressive symptoms, compared with those with ,6
depressive symptoms, had an 82% higher risk of either functional decline or death, whereas
the intermediate levels of depressive symptoms showed intermediate risk (p 5 0.003 for
trend). A similar graded association was found for functional decline and death separately;
however, after multivariate analysis, the association with mortality was less strong and no
longer statistically significant.
CONCLUSIONS An increasing number of depressive symptoms is a negative prognostic factor for patients with
heart failure, just as it is for patients with CHD. (J Am Coll Cardiol 2001;38:199–205) ©
2001 by the American College of Cardiology
Depression is a relatively common condition among indi-
viduals with heart failure, with rates reported from 24% (1)
to .40% (2) in patients with stable ambulatory heart failure.
In patients with coronary heart disease (CHD), depression
is associated with poor outcomes, including recurrent car-
diac events (3,4), mortality (5–8) and low functional status
or quality of life (9,10). These associations exist both when
the risk factor is a major depressive episode (4,7) and when
a high level of depressive symptoms occur in the absence of
a clinical diagnosis of depression (5,8,11).
Despite the established role of depression as a prognostic
factor in patients with CHD, little is known about whether
depression plays a similar role in patients with heart failure.
A link between depressive symptoms and the course of heart
failure may be expected, because depressed individuals have
elevated sympathoadrenal activation (12–15), a response
that may be deleterious for patients with heart failure
(16,17). Accordingly, the present study examined whether
depressive symptoms increased the risk of death and dis-
ability in a consecutive sample of patients meeting clinical
criteria for heart failure on hospital admission.
METHODS
Study sample and general procedures. We studied con-
secutive patients $50 years of age admitted to Yale-New
Haven Hospital in a 2.5-year period (March 1996 to
September 1998) who met clinical criteria for the presence
of heart failure on hospital admission. Yale-New Haven
Hospital is a 900-bed hospital affiliated with Yale University
and is the largest community hospital serving New Haven,
Connecticut. To be eligible for the study, patients were
identified with either a hospital admission diagnosis of heart
failure or radiologic signs of heart failure on the admission
chest X-ray film. Patients who met either of these condi-
tions had their medical records reviewed to verify a set of
additional criteria of symptoms and signs (18,19). At least
one of the following symptoms had to be present on
admission or had to have precipitated the patient’s hospital
admission: new onset or worsening of symptoms of respi-
ratory distress (e.g., dyspnea or shortness of breath at rest or
during exertion, orthopnea, paroxysmal nocturnal dyspnea),
chest pain consistent with myocardial ischemia or nonspe-
cific symptoms that may be manifestations of heart failure
(e.g., fatigue, confusion or disorientation, loss of conscious-
ness, syncope). At least one of the following signs had to be
present on the admission physical examination: S3 gallop,
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bilateral pulmonary rales or crackles, hypotension or cardio-
genic shock, cardiac arrest, respiratory rate $24 breaths/
min, peripheral edema, cardiac tachyarrhythmias or conduc-
tion disorders (e.g., atrioventricular block of second degree
or higher, left bundle branch block, bifascicular block).
Although some of the qualifying symptoms and signs may
appear nonspecific, they apply to patients who have already
passed the first phase of screening (i.e., patients who have
either signs of heart failure on the admission chest X-ray
film or an admitting diagnosis of heart failure). Excluded
from the study were patients transferred from other hospi-
tals, patients admitted from nursing homes, patients with
heart failure secondary to high-output states or noncardiac
diseases and patients with a terminal illness in addition to
heart failure. The Institutional Review Board approved the
study, and all patients provided informed consent. Within
three days of hospital admission, patients who met criteria
for heart failure were interviewed face to face to assess study
variables, as described subsequently. Medical charts were
reviewed after hospital discharge.
Study measures. ASSESSMENT OF DEPRESSIVE SYMPTOMS.
Depressive symptoms were assessed by means of the Geri-
atric Depression Scale (GDS), Short-Form, which is a
validated 15-item, self-report depressive symptom scale
designed to detect the presence of current depression in
older adults (20). The GDS is one of the most commonly
used instruments for depression screening among older
adults (21,22), and it is well suited to measure depressive
symptoms in severely ill patients in the hospital, because it
focuses on the nonsomatic symptoms of depression (23).
Using a cut-off point of six or more symptoms, this scale has
a sensitivity between 88% to 92% and a specificity between
62% to 81%, as compared with a structured clinical inter-
view for depression (21,24). Consistent with previous stud-
ies (20,22), we defined the presence of clinically relevant
depressive symptoms as $6 symptoms, with 6 to 7 symp-
toms indicating a mild level of depressive symptoms, 8 to 10
symptoms indicating a moderate level of depressive symp-
toms and $11 symptoms indicating a severe level of
depressive symptoms.
BASELINE HEALTH STATUS, PHYSICAL FUNCTION AND CLIN-
ICAL VARIABLES. Patients were asked about their level of
physical function in the month before hospital admission,
using self-assessments suitable for severely ill in-patients.
We measured the patients’ functional capability in activities
of daily living (ADL), given the impact of a decline in ADL
on the quality of life of patients with heart failure (25,26).
Limitations in ADL were assessed by means of the ADL
scale by Katz et al. (27), which measures with high accuracy
(28–30) the self-reported ability to perform one or more of
the following activities without the help of another person:
moving from bed to chair, using the toilet, bathing, dress-
ing, eating and walking across a small room. We also
assessed physical limitations due to dyspnea by means of the
Dyspnea Index (31,32). Dyspnea at rest was defined as the
presence of shortness of breath at rest, while sitting or lying
down.
Patients were asked about their history of heart failure
through questions on shortness of breath, orthopnea and
paroxysmal nocturnal dyspnea, similar in structure to the
Rose questionnaire on chronic conditions (33). They were
also asked whether they had been previously admitted to the
hospital for congestive heart failure or shortness of breath.
Information on other medical history, suspected factors that
precipitated the hospital admission, clinical characteristics
on admission, treatment with angiotensin-converting en-
zyme inhibitors at discharge and left ventricular ejection
fraction (LVEF) were abstracted from the medical records.
If LVEF was not obtained during the index hospital period,
previous values were recorded, if available. In our sample,
71% of the patients had LVEF assessed during the index
admission; 13% had a previous value obtained within the
past six months before admission and 17% had a value
obtained earlier than six months before admission.
Study outcomes. The main outcome of the study was a
combined end point of either death or decline in ADL
function at six months after the index hospital admission.
The rationale for the use of this combined outcome is that
death can be considered as the worst functional status (34);
therefore, exclusion of patients who died before being able
to provide information on functional status at follow-up
could bias the results (35). Death and functional decline
among survivors at six months, however, were also exam-
ined separately. Follow-up assessments were done in a
blinded fashion with respect to depression status and GDS
scores. At one and six months, patients were contacted by
phone to ascertain their vital status and functional status by
means of Katz’s ADL scale, the same as in the baseline
interview. At six months, vital status was known for all the
patients and functional status was known for .95% of the
surviving patients. Decline in ADL function was defined as
a greater number of ADL limitations at six months than at
baseline. Five patients who had a functional decline by one
month after discharge and for whom information on ADL
function at six months was not available were classified as
having a decline in ADL function.
Statistical analysis. First, we compared mean GDS de-
pressive symptom scores according to the levels of baseline
demographic factors, medical history, other baseline vari-
ables and LVEF by using the Student t test or analysis of
variance. Next, we conducted multivariable regression anal-
yses that modeled the relative risk of study outcomes (i.e.,
death or decline in ADL function at six months) according
to the levels of depressive symptoms at baseline, as defined
Abbreviations and Acronyms
ADL 5 activities of daily living
CHD 5 coronary heart disease
GDS 5 Geriatric Depression Scale
LVEF 5 left ventricular ejection fraction
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earlier, after adjusting for other baseline factors (i.e., demo-
graphic characteristics, medical history, baseline functional
status, clinical characteristics on presentation and LVEF).
This was accomplished by means of a generalized linear
model with a binomial error distribution and a logarithmic
link (36).
We fitted three sequential models. In the first model, we
adjusted for demographic factors only. In the second model,
we added medical history and baseline functional status. In
the third model, we added clinical severity features (i.e.,
clinical characteristics on presentation and LVEF). At each
step, variables considered for inclusion were those associated
with the GDS depressive symptom score, at p , 0.20 in the
bivariate analyses (37).
All tests for statistical significance were two-tailed with
an alpha level of 0.05. All analyses were conducted using
SAS software, release 6.12 (Cary, North Carolina).
RESULTS
Study sample. In the study period, 1,148 consecutively
admitted patients were screened for study eligibility. A total
of 520 met the eligibility criteria, and of these, 426 patients
(81.9%) were enrolled. We excluded patients with a missing
GDS score (n 5 13), missing baseline functional status (n 5
3) or missing follow-up functional status, unless the patients
had died or had already declined in ADL function by one
month (n 5 16). Three additional patients were excluded
because their medical records could not be located, which
meant missing information on all clinical variables. These
exclusions yielded a final sample of 391 patients.
Bivariate analyses. Lower education and non-black race
were associated with higher depressive symptom scores
(Table 1). Women also tended to have higher depressive
symptom scores compared with men, but there was no
association with age.
With respect to medical history, previous myocardial
infarctions and previous hospital admissions for heart failure
were significantly associated with higher depressive symp-
tom scores. A history of diabetes also showed a borderline
association with higher GDS scores. Baseline functional
status, including ADL limitations and dyspnea at rest, were
strongly related to depressive symptoms.
Depressive symptoms were commonly noted: of all pa-
tients, 35% scored in the mild range, 33.5% in the moderate
range and 9% in the severe range. There was no association
between depressive symptom scores and suspected factors
precipitating the current heart failure episode, including
nonadherence to medications, uncontrolled hypertension,
tachyarrhythmia and myocardial ischemia. Similarly, clinical
presentation characteristics showed little relationship with
depressive symptoms, with the exception of systolic blood
pressure, which was inversely associated with depressive
symptoms. There was no association between GDS score
and clinical management, such as the likelihood of obtain-
ing an ejection fraction measurement during the index
admission or angiotensin-converting enzyme inhibitor
treatment on discharge (data not shown).
When the rates for the combined end point of a decline
in ADL activities or death at six months were examined
according to depressive symptom severity at baseline, a
strong and graded association was found (Table 2). The
higher the level of depressive symptoms, the higher the rate
of either functional decline or death at six months. For the
combined end point, the rates increased from 30.7% in the
absence of clinically relevant depressive symptoms to 60% in
the presence of severe depressive symptoms (p 5 0.001 for
trend). When the rates of functional decline and death were
examined separately, a similar graded association was found
between depressive symptoms and each of these two out-
comes (Table 2).
Multivariable analyses. To determine whether the associ-
ation between depressive symptoms and the study outcomes
was independent of demographic factors, medical history,
baseline functional status and clinical severity (i.e., clinical
characteristics on presentation and LVEF), we adjusted for
these covariables in a series of sequential models (Table 3).
After adjusting for all of these factors, patients with severe
depressive symptoms, compared with those without clini-
cally relevant depressive symptoms, had an 82% higher risk
of either functional decline or death, whereas the interme-
diate levels of depressive symptoms showed intermediate
risk. Adjustment for baseline health status and clinical
severity had a greater impact on the association between
depressive symptoms and mortality than on the association
between depressive symptoms and functional decline (Table
3). After adjusting for all of these factors, increasing levels of
depressive symptoms retained a strong and significant trend
toward a higher decline in functional status, whereas the
trend for higher mortality was no longer statistically signif-
icant.
DISCUSSION
Effect of depression on functional decline and death in
patients with heart failure. Depressive symptoms occurred
commonly in this population, as noted by others (1,2,38).
The prevalence of depressive symptoms was higher in our
study than in previous reports, which might be due to the
fact that our group consisted of severely ill in-patients,
whereas other studies typically focused on patients with
stable, ambulatory heart failure (1,2).
We found that, among patients admitted to the hospital
for heart failure, an increasing number of depressive symp-
toms was associated with a significantly higher risk of the
combined end point of functional decline or death. The
association was strong and graded, with higher risks asso-
ciated with higher depressive symptom scores, and was not
explained by sociodemographic factors, baseline functional
status, medical history or other baseline characteristics.
Virtually no previous study has addressed the link be-
tween depression and functional outcomes in heart failure.
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Table 1. Geriatric Depression Scale Scores According to Level
of Baseline Characteristics
Characteristics n
Mean 6 SD
GDS Score
p
Value*
Demographic factors
Age (years)
,65 101 7.57 6 2.20
65–74 106 7.11 6 2.21 0.30
$75 184 7.25 6 2.12
Gender
Male 198 7.11 6 1.99 0.09
Female 193 7.49 6 2.32
Race
Non-black 312 7.42 6 2.11 0.02
Black 79 6.81 6 2.33
Marital status
Not married 207 7.38 6 2.26 0.41
Married 183 7.20 6 2.05
Education (years)
,9 86 7.81 6 2.18 0.004
9–12 185 7.21 6 2.21
.12 114 6.92 6 1.97
Medical history and cardiovascular
risk factors
History of MI
No 207 7.04 6 2.15 0.01
Yes 184 7.58 6 2.16
History of heart failure
No 93 7.02 6 2.10 0.02
Yes, without previous
hospital admissions for
heart failure
140 7.06 6 1.95
Yes, with previous hospital
admissions for heart failure
158 7.67 6 2.33
History of hypertension
No 111 7.41 6 2.15 0.50
Yes 280 7.25 6 2.17
History of diabetes
No 205 7.10 6 2.11 0.06
Yes 186 7.51 6 2.21
History of renal insufficiency
No 257 7.24 6 2.09 0.45
Yes 134 7.41 6 2.31
History of chronic angina
No 241 7.25 6 2.18 0.61
Yes 150 7.37 6 2.15
Current smoking
No 339 7.30 6 2.14 0.82
Yes 48 7.23 6 2.39
History of alcohol abuse
No 316 7.26 6 2.15 0.28
Yes 75 7.47 6 2.23
Body mass index (kg/m2)
,25 155 7.28 6 2.10 0.94
25–29 117 7.24 6 2.20
$30 116 7.31 6 2.22
Baseline functional status
ADL disability in month before admission
None 308 7.07 6 2.11 0.0001
1 ADL limitation 32 7.38 6 1.95
.1 ADL limitation 51 8.59 6 2.21
Dyspnea at rest in month
before admission
No 284 6.97 6 2.07 0.0001
Yes 107 8.16 6 2.20
Suspected factors precipitating
current heart failure episode
Nonadherence with medications
No 281 7.28 6 2.04 0.78
Yes 110 7.34 6 2.46
(Continued)
Table 1. Continued
Characteristics n
Mean 6 SD
GDS Score
p
Value*
Uncontrolled hypertension
No 292 7.33 6 2.14 0.67
Yes 94 7.22 6 2.28
Tachyarrhythmia
No 315 7.32 6 2.22 0.77
Yes 71 7.24 6 2.01
Myocardial ischemia
No 190 7.32 6 2.22 0.92
Yes 196 7.29 6 2.14
Clinical characteristics on admission
First systolic blood pressure (mm Hg)
,120 72 8.08 6 2.29 0.002
120–139 83 7.00 6 1.81
140–149 88 7.68 6 2.25
$160 147 6.85 6 2.12
Serum creatinine on admission (mg/dl)
#2.5 340 7.36 6 2.17 0.11
.2.5 51 6.84 6 2.08
Serum sodium on admission (mmol/l)
,130 22 7.82 6 2.20 0.25
$130 369 7.26 6 2.16
Serum glucose on admission (mg/dl)
#200 278 7.28 6 2.21 0.83
.200 98 7.34 6 2.11
Elevated CK-MB in first 24 h
No 347 7.35 6 2.18 0.21
Yes 44 6.91 6 2.02
Respiratory rate (breaths/min)
#24 219 7.37 6 2.17 0.22
.24 158 7.10 6 2.10
Pulse (beats/min)
#100 262 7.43 6 2.20 0.08
.100 129 7.02 6 2.07
S3 gallop
No 301 7.27 6 2.18 0.76
Yes 82 7.35 6 2.14
Cardiomegaly on chest X-ray film
No 249 7.39 6 2.16 0.49
Yes 124 7.23 6 2.14
Pulmonary edema on chest
X-ray film
No 224 7.32 6 2.04 0.91
Yes 162 7.30 6 2.31
First ECG findings
Ischemic changes
No 201 7.36 6 2.19 0.48
Yes 188 7.21 6 2.13
Atrial fibrillation or flutter
No 291 7.32 6 2.22 0.62
Yes 98 7.19 6 1.99
Left ventricular hypertrophy
No 319 7.34 6 2.14 0.30
Yes 70 7.04 6 2.26
LVEF
,20% 48 7.90 6 2.18 0.13
20–29% 78 7.50 6 1.98
30–39% 73 6.86 6 2.23
40–54% 73 7.23 6 2.14
$55% 115 7.25 6 2.22
*Where appropriate, trend tests were used. Patient numbers do not always total to 391
because of missing values.
ADL 5 activities of daily living; CK-MB 5 creatine kinase-MB fraction; ECG 5
electrocardiographic; GDS 5 Geriatric Depression Scale; LVEF 5 left ventricular
ejection fraction; MI 5 myocardial infarction.
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An earlier cross-sectional study reported higher levels of
disability among patients with heart failure with increasing
levels of depression (39). Using a prospective design, our
study demonstrated a strong relationship between the level
of depressive symptoms at baseline and subsequent func-
tional decline in patients with heart failure.
When we examined mortality as a separate outcome, a
clear, albeit nonsignificant trend was found between in-
creasing depressive symptom levels and higher mortality
rates at six months. The latter is consistent with previous
studies (38,40,41), which showed mild to moderate associ-
ations between depression and mortality in patients with
heart failure, although the difference was statistically signif-
icant in only in one of the studies (40). In our study, after
adjusting for baseline characteristics, the effect of depressive
symptoms on mortality was weaker than its effect on
functional decline.
Potential mechanisms. A number of potential explana-
tions are possible for the association described earlier. First,
higher depressive symptom levels at baseline may have been
secondary to a greater clinical severity of heart failure. Such
a circumstance could make it falsely appear as if depressive
symptoms increased the risk of adverse outcomes, when, in
fact, the higher risk was simply a function of disease
severity. However, this explanation seems unlikely, because
we adjusted for a number of medical history and clinical
factors indicative of disease severity, including baseline
functional status, dyspnea at rest, previous hospital admis-
sions for heart failure and LVEF.
Second, depressed persons may become increasingly de-
pressed over time and may therefore be more likely to report
more disabilities over time, even when their functional
status has actually remained stable (42,43). This explanation
is also unlikely, because, as described earlier, we also found
Table 2. Distribution of Outcome Events (Death and Functional Decline) According to Severity of Depression at Baseline
Depressive
Symptom
Level
Functional Decline or Death
Functional Decline Among
Survivors at 6 Months Death
No. of
Events/Total
Population
Event Rate
(%)
p Value
for Trend
No. of
Events/Total
Population
Event Rate
(%)
p Value
for Trend
No. of
Events/Total
Population
Event Rate
(%)
p Value
for Trend
Normal 27/88 30.7 17/78 21.8 10/88 11.4
Mild 47/137 34.3
0.001
25/115 21.7
0.004
22/137 16.1
0.02
Moderate 64/131 48.9 35/102 34.3 29/131 22.1
Severe 21/35 60.0 12/26 46.2 9/35 25.7
Normal 5 Geriatric Depression Scale (GDS) score ,6; mild 5 GDS score between 6 and 7; moderate 5 GDS score between 8 and 10; severe 5 GDS score .10.
} } }
Table 3. Risk Ratios and 95% Confidence Interval of Study Outcomes at Six Months by Level of Depression at Baseline
Depressive Symptom Level
Functional Decline or Death
Functional Decline Among
Survivors at 6 Months Death
RR 95% CI
p Value
for Trend RR 95% CI
p Value
for Trend RR 95% CI
p Value
for Trend
Model 1—adjusted for demographic
factors†
Normal 1.00 — 1.00 — 1.00 —
Mild 1.17 0.80–1.73
0.0001
1.07 0.62–1.86
0.005
1.56 0.73–3.32
0.006
Moderate 1.61 1.12–2.33 1.62 0.97–2.71 2.20 1.05–4.60
Severe 2.19 1.46–3.27 2.31 1.28–4.16 3.22 1.27–8.18
Model 2—adjusted for demographic
factors, medical history and
baseline functional status‡
Normal 1.00 — 1.00 — 1.00 —
Mild 1.15 0.79–1.68
0.002
1.09 0.63–1.89
0.004
1.46 0.69–3.10
0.10
Moderate 1.41 0.97–2.06 1.61 0.94–2.75 1.58 0.74–3.39
Severe 2.00 1.31–3.04 2.51 1.35–4.68 2.25 0.87–5.81
Model 3—adjusted for all
aforementioned and clinical
characteristics§
Normal 1.00 — 1.00 — 1.00 —
Mild 1.10 0.75–1.62
0.004
1.15 0.66–2.00
0.01
1.07 0.49–2.33
0.27
Moderate 1.39 0.95–2.04 1.65 0.96–2.83 1.25 0.58–2.70
Severe 1.82 1.19–2.78 2.16 1.15–4.06 1.68 0.63–4.45
Normal 5 Geriatric Depression Scale (GDS) score ,6; mild 5 GDS score between 6 and 7; moderate 5 GDS score between 8 and 10; severe 5 GDS score .10. †Age, gender,
race, education. ‡History of myocardial infarction, history of diabetes, previous hospital admissions for heart failure, number of activities of daily limitations and dyspnea at rest
in the month before hospital admission. §Clinical features on presentation (systolic blood pressure, serum creatinine $2.5 mg/dl, pulse .100 beats/min) and left ventricular
ejection fraction.
CI 5 confidence interval; RR 5 risk ratio.
} } }
} } }
} } }
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a trend for depressive symptoms to increase the risk of
mortality, an end point that is not susceptible to this type of
bias.
Third, the association we observed may have been medi-
ated by unhealthy behaviors, such as smoking and excessive
alcohol consumption. In our data, however, depressive
symptoms were not significantly associated with smoking or
a history of alcohol abuse; therefore, it is unlikely that these
factors play a major role. Nonetheless, other behaviors could
have mediated the association we observed. For example,
there is evidence that depression reduces the likelihood that
one will take medication properly, follow dietary advice or
adhere to other aspects of medical regimens (44,45). In our
study, however, we failed to find a baseline association
between nonadherence to medications and depressive symp-
toms. This suggests that noncompliance with medical reg-
imens should not play a major role in our findings. Yet, we
did not have reliable information on adherence to medical
regimens during the follow-up; therefore, we cannot com-
pletely measure the role of this factor in our results.
Fourth, depression may worsen the prognosis of heart
failure through direct physiologic mechanisms. Depression
has been associated with excessive activation of the sympa-
thetic nervous system. Hypersecretion of norepinephrine in
depressed patients has been documented by the presence of
elevated norepinephrine and its metabolites in plasma and
urine (12–15), and treatment with tricyclic antidepressants
decreases plasma and urinary levels of norepinephrine and
its metabolites (46,47). Heart failure is accompanied by
heightened activation of the sympathetic nervous system.
This initially aids the failing heart, but eventually is thought
to play a major role in the progression of heart failure
(16,17). Neurohormonal activation may exacerbate the he-
modynamic abnormalities of heart failure by increasing the
heart rate and inducing vasoconstriction and sodium reten-
tion. In addition, increased activity of the sympathoadrenal
system may predispose patients to arrhythmias and sudden
death (48). Therefore, by further increasing the level of
sympathetic activity, which is already elevated in heart
failure, depression may foster disease progression. Depres-
sion is also associated with impaired vagal tone and reduced
heart rate variability (49,50), which is also a risk factor for
cardiovascular morbidity and mortality (51,52). Because we
did not have information on variables of sympathetic and
parasympathetic nervous system activation, these mecha-
nisms remain speculative. Nevertheless, such explanations
are biologically plausible.
Study limitations. This study had some potential limita-
tions. First, although the GDS is a valid measure of
depressive symptoms among older persons, it is not synon-
ymous with a clinical diagnosis of depression. However, we
found no evidence of a threshold effect. On the contrary,
there was a graded effect, with an increasing level of
depressive symptoms being associated with a risk of higher
outcomes. Therefore, a symptom checklist assessing the
amount of depressive symptomatology may be more useful
than a dichotomous diagnosis. In addition, from a practical
standpoint, the GDS is easier to administer than a struc-
tured interview for clinical diagnosis of depression, and it
does not require a mental health specialist. Therefore, it
may provide a more feasible means of identifying depressed
patients with heart failure who are in need of special
attention.
A second weakness of our study was the lack of informa-
tion on adherence to medical regimens during follow-up.
Thus, we were not able to determine whether adherence
after hospital discharge may have explained the relationship
between depressive symptoms and risk of disability and
death. However, the lack of association between adherence
and depressive symptoms at baseline suggests that adher-
ence may not have played an important role in our study.
Finally, although our sample was larger than previous
studies, its size did not provide adequate power to examine
mortality as a separate end point.
Conclusions. The present study provides strong evidence
that depressive symptoms represent a negative prognostic
factor in patients with heart failure, just as they do for
patients with CHD. Early identification and treatment of
depressive symptoms and clinical depression should provide
an important tool for decreasing the morbidity and mortal-
ity of heart failure.
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